MedGenesis Therapeutix Inc.

MedGenesis Therapeutix MedGenesis is a privately-held biopharmaceutical company committed to developing and commercializing highly innovative treatments for patients with serious neurologic disease. MedGenesis lead program, glial cell-line derived neurotrophic factor GDNF, is a potentially disease-modifying treatment for Parkinsons disease that has recently completed Phase 2 clinical studies. The program is the first to use MedGenesis proprietary intermittent convection-enhanced delivery .

OVERVIEW

The web site medgenesis.com currently has a traffic classification of zero (the smaller the more traffic). We have traversed two pages inside the website medgenesis.com and found five websites referencing medgenesis.com. I observed one contacts and directions for medgenesis.com to help you communicate with them. The web site medgenesis.com has been on the internet for nine hundred and five weeks, six days, five hours, and fifty-one minutes.
Pages Parsed
2
Links to this site
5
Contacts
1
Addresses
1
Online Since
Mar 2008

MEDGENESIS.COM TRAFFIC

The web site medgenesis.com has seen alternating quantities of traffic all through the year.
Traffic for medgenesis.com

Date Range

1 week
1 month
3 months
This Year
Last Year
All time
Traffic ranking (by month) for medgenesis.com

Date Range

All time
This Year
Last Year
Traffic ranking by day of the week for medgenesis.com

Date Range

All time
This Year
Last Year
Last Month

MEDGENESIS.COM HISTORY

The web site medgenesis.com was began on on March 08, 2008. This web site was updated on the date of January 11, 2011. This web page will expire on the date of June 23, 2016. As of today, it is nine hundred and five weeks, six days, five hours, and fifty-one minutes old.
REGISTERED
March
2008
UPDATED
January
2011
EXPIRED
June
2016

WEBPAGE PERIOD

17
YEARS
4
MONTHS
5
DAYS

LINKS TO WEBSITE

Ready to Rocket

Thursday, February 26, 2015. Ready to Rocket Presentation 2015. Here is the briefing provided to investors and advisors of technology companies in Vancouver on February 26th 2015 at Harbour Centre.

Kieran Breens Blog

Now that 2014 has arrived, this is a good time to reflect on 2013 and what we have been achieved. So, here are some of the highlights of what we have achieved. 1 We funded over 5million in research grants. This brings our total spend on research to over 65million since the charity started.

Prince Edward Island, Canada July 13-15, 2014

If you have signed up, you should have already received your welcome email with log-in details. This presentation is a spec.

WHAT DOES MEDGENESIS.COM LOOK LIKE?

Desktop Screenshot of medgenesis.com Mobile Screenshot of medgenesis.com Tablet Screenshot of medgenesis.com

CONTACTS

Cagley, Leslie

302-608 Broughton Street

Victoria, BC, V8W 1C7

CA

MEDGENESIS.COM SERVER

Our crawlers identified that the main root page on medgenesis.com took four hundred and thirty-eight milliseconds to download. I could not observe a SSL certificate, so in conclusion our web crawlers consider this site not secure.
Load time
0.438 sec
SSL
NOT SECURE
IP
198.57.220.166

NAME SERVERS

ns1.greslie.com
ns2.greslie.com

SERVER SOFTWARE AND ENCODING

We found that this domain is implementing the Microsoft-IIS/7.5 os.

SITE TITLE

MedGenesis Therapeutix Inc.

DESCRIPTION

MedGenesis Therapeutix MedGenesis is a privately-held biopharmaceutical company committed to developing and commercializing highly innovative treatments for patients with serious neurologic disease. MedGenesis lead program, glial cell-line derived neurotrophic factor GDNF, is a potentially disease-modifying treatment for Parkinsons disease that has recently completed Phase 2 clinical studies. The program is the first to use MedGenesis proprietary intermittent convection-enhanced delivery .

PARSED CONTENT

The web site medgenesis.com had the following in the homepage, "MedGenesis Therapeutix MedGenesis is a privately-held biopharmaceutical company committed to developing and commercializing highly innovative treatments for patients with serious neurologic disease." I saw that the webpage stated " MedGenesis lead program, glial cell-line derived neurotrophic factor GDNF, is a potentially disease-modifying treatment for Parkinsons disease that has recently completed Phase 2 clinical studies." They also said " The program is the first to use MedGenesis proprietary intermittent convection-enhanced delivery ."

ANALYZE SIMILAR WEB SITES

как правильно рвать целку видио - medgenesis.ru

Порно фильм sex lies internet смотреть онлайн. Грудастая мамаша отсосала сыну перед веб камерой. Рассказы про это с тещейсемейное порно. Фото брат забрался в постель к сестре.

НИИ медицинской генетики Главная

Томск, Набережная реки Ушайки, 10. Конференция СОВРЕМЕННЫЕ МОЛЕКУЛЯРНО-БИОЛОГИЧЕСКИЕ И ГЕНЕТИЧЕСКИЕ ТЕХНОЛОГИИ В МЕДИЦИНСКОЙ ПРАКТИКЕ.

medizinische genetik Herausgegeben von der Deutschen Gesellschaft für Humangenetik e.V.

Organ der Deutschen Gesellschaft für Humangenetik, der Österreichischen Gesellschaft für Humangenetik, der Schweizerischen Gesellschaft für Medizinische Genetik und des Berufsverbandes Deutscher Humangenetiker. Der Zeitschrift medizinischegenetik ab 2007. Die Deutsche Gesellschaft für Humangenetik bietet auf ihrer Website.

MEDGENICS.COM

Unlocking the potential of gene therapy for patients with rare and orphan diseases. At Medgenics, we share one singular focus - to transform the lives of our patients through the development of innovative and best-in-class therapies. TARGT has demonstrated several advantages over current gene or protein therapy, including efficacy, safety and capital efficiency.

about banc de binary about banc de binary

She said at the appeal launch in banc de binary Sydney on banc de binary Thursday. The AFP denied they were discriminating, banc de binary The RSPCA seized 11 horses in banc de binary 2012 after inspecting the paddocks in banc de binary Cobbitty, banc de binary.